{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:58:29Z","timestamp":1781056709898,"version":"3.54.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Sacral neuromodulation (SNM) is an established therapy for refractory bowel and lower urinary tract dysfunction. While its efficacy and patient satisfaction are well documented, little is known about the physical burden of the implant itself. This study aimed to evaluate patient perspectives on the implantable pulse generator (IPG) placed in the gluteal region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed 100 consecutive patients who underwent SNM within the past 2 years at a tertiary care center. Data were collected during follow-up visits or phone interviews using a five-question survey based on common patient concerns. Responses were analyzed descriptively, with statistical testing performed using SPSS version 29.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty-two patients received SNM for overactive bladder, 16 for urinary retention, and two for fecal incontinence. Sixty-two percent reported awareness of the IPG, 18% reported sleep or movement limitations, and 36% reported activity-related discomfort. Eleven percent turned off the device for non-MRI reasons. Overweight or obese patients (BMI &gt;25) were less likely to report disturbances compared with normal-weight patients. Male patients were more likely than female patients to deactivate their device (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.014), while older patients were less likely to turn it off.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Most patients tolerated SNM well, though lower BMI was associated with greater discomfort, consistent with prior reports of higher revision rates in leaner individuals. Sex- and age-related differences suggest variations in device use behaviors, possibly due to lifestyle, activity level, or technological engagement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SNM is generally well tolerated, but leaner, younger, and male patients may experience greater device-related burden, highlighting the need for tailored counseling and device optimization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00192-026-06756-8","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:01:08Z","timestamp":1781010068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patients\u2019 Perspectives and Challenges with Sacral Neuromodulation Implantable Pulse Generator"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1992-2318","authenticated-orcid":false,"given":"Mazen","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Fahmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad El","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Trump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Abou","family":"Zeinab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Albakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard B.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"6","key":"6756_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327\u201336.","journal-title":"World J Urol"},{"issue":"2","key":"6756_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/j.gastro.2009.04.054","volume":"137","author":"WE Whitehead","year":"2009","unstructured":"Whitehead WE, et al. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology. 2009;137(2):512\u20137.","journal-title":"Gastroenterology"},{"key":"6756_CR3","unstructured":"US Food and Drug Administration. Summary of safety and effectiveness data (SSED): InterStim System. 2011.https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf8\/p080025b.pdf"},{"issue":"3","key":"6756_CR4","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/01.ju.0000134418.21959.98","volume":"172","author":"MR van Balken","year":"2004","unstructured":"van Balken MR, et al. Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol. 2004;172(3):980\u20133.","journal-title":"J Urol."},{"issue":"2","key":"6756_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/DCR.0b013e318276b24c","volume":"56","author":"T Hull","year":"2013","unstructured":"Hull T, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56(2):234\u201345.","journal-title":"Dis Colon Rectum."},{"issue":"3","key":"6756_CR6","first-page":"847","volume":"39","author":"G Lombardi","year":"2020","unstructured":"Lombardi G, Musco S, Celso M, et al. Patient perception of sacral neuromodulation for lower urinary tract dysfunction: a 10-year single-center experience. Neurourol Urodyn. 2020;39(3):847\u201354.","journal-title":"Neurourol Urodyn."},{"issue":"8","key":"6756_CR7","first-page":"1440","volume":"30","author":"AP Cameron","year":"2011","unstructured":"Cameron AP, Anger JT, Madison R, et al. Complications of sacral neuromodulation in the Medicare population. Neurourol Urodyn. 2011;30(8):1440\u20135.","journal-title":"Neurourol Urodyn."},{"issue":"5","key":"6756_CR8","first-page":"540","volume":"28","author":"S Ismail","year":"2009","unstructured":"Ismail S, Kessler TM, Fisch M, et al. Surgical revisions and complications of sacral neuromodulation: a single center long-term experience. Neurourol Urodyn. 2009;28(5):540\u20133.","journal-title":"Neurourol Urodyn."},{"issue":"5","key":"6756_CR9","first-page":"338","volume":"22","author":"R Nardos","year":"2016","unstructured":"Nardos R, Benson K, Hurtado EA, et al. Body mass index and complications after sacral neuromodulation. Female Pelvic Med Reconstr Surg. 2016;22(5):338\u201342.","journal-title":"Female Pelvic Med Reconstr Surg."},{"issue":"5","key":"6756_CR10","first-page":"646","volume":"26","author":"A Hijaz","year":"2007","unstructured":"Hijaz A, Vasavada SP, Daneshgari F, et al. Complications and troubleshooting of sacral neuromodulation therapy: a review. Neurourol Urodyn. 2007;26(5):646\u201353.","journal-title":"Neurourol Urodyn."},{"issue":"6","key":"6756_CR11","first-page":"511","volume":"34","author":"K Noblett","year":"2015","unstructured":"Noblett K, Benson K, Kreder KJ, et al. Clinical and patient-reported outcomes of InterStim therapy for overactive bladder: a systematic review. Neurourol Urodyn. 2015;34(6):511\u20137.","journal-title":"Neurourol Urodyn."},{"issue":"13","key":"6756_CR12","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1001\/jama.2016.14617","volume":"316","author":"CL Amundsen","year":"2016","unstructured":"Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs sacral neuromodulation for refractory urgency urinary incontinence: a randomized trial. JAMA. 2016;316(13):1366\u201374.","journal-title":"JAMA."},{"key":"6756_CR13","doi-asserted-by":"publisher","DOI":"10.2196\/48654","volume":"26","author":"N Wang","year":"2024","unstructured":"Wang N, Zhou S, Liu Z, Han Y. Perceptions and satisfaction with the use of digital medical services in urban older adults of China: mixed methods study. J Med Internet Res. 2024;26:e48654.","journal-title":"J Med Internet Res"},{"key":"6756_CR14","unstructured":"Medtronic. InterStim System MRI Guidelines. 2023.\u00a0https:\/\/www.medtronic.com\/us-en\/healthcare-professionals\/products\/urology\/interstim-systems\/interstim-x-system\/mri.html"},{"key":"6756_CR15","unstructured":"Medtronic.\u00a0Living with InterStim\u2122 therapy\u00a0\u2013 travel and airport security guidelines. Available at:\u00a0https:\/\/www.medtronic.com\/\u00a0(Accessed August 9, 2025)."},{"issue":"6","key":"6756_CR16","first-page":"1935","volume":"39","author":"HB Goldman","year":"2020","unstructured":"Goldman HB, Amundsen CL, Appell RA, et al. Efficacy and safety of a new rechargeable sacral neuromodulation system for the treatment of overactive bladder syndrome. Neurourol Urodyn. 2020;39(6):1935\u201343.","journal-title":"Neurourol Urodyn."}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-026-06756-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-026-06756-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-026-06756-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:04:22Z","timestamp":1781053462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-026-06756-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":16,"alternative-id":["6756"],"URL":"https:\/\/doi.org\/10.1007\/s00192-026-06756-8","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with institutional and ethical standards. Ethical approval was obtained from the Institutional Review Board (IRB 23-381). Owing to the retrospective nature of the study, the requirement for informed consent was waived by the institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}